Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors.

Liu S, Chang Y, Ma J, Li X, Li X, Fan J, Huang R, Duan G, Sun X.

Oncol Lett. 2013 Dec;6(6):1641-1645. Epub 2013 Oct 9.

2.

p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas.

Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R.

Gynecol Oncol. 2004 Oct;95(1):37-45.

PMID:
15385108
3.

Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.

Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.

Int J Cancer. 2014 Jul 1;135(1):128-37. doi: 10.1002/ijc.28675. Epub 2014 Jan 6.

4.

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.

Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, Park YS.

J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016.

6.

Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.

Kim HS, Lee HS, Kim WH.

Cancer Res Treat. 2011 Sep;43(3):181-8. doi: 10.4143/crt.2011.43.3.181. Epub 2011 Sep 30.

7.

High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Cigrovski Berković M, Čačev T, Catela Ivković T, Marout J, Ulamec M, Zjačić-Rotkvić V, Kapitanović S.

Mol Cell Endocrinol. 2016 Apr 15;425:61-8. doi: 10.1016/j.mce.2016.01.013. Epub 2016 Jan 19.

PMID:
26805636
8.

[Alterations of cell cycle regulating proteins: Rb, p21 and p16 in laryngeal cancer].

Pietruszewska W, Durko M, Kobos J.

Otolaryngol Pol. 2007;61(6):951-7. doi: 10.1016/S0030-6657(07)70559-0. Polish.

PMID:
18546941
9.

Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.

Er LM, Li Y, Wu ML, Zhao Q, Tan BB, Wang XL, Wang SJ.

Oncol Lett. 2017 Apr;13(4):2391-2396. doi: 10.3892/ol.2017.5735. Epub 2017 Feb 14.

10.

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.

Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ.

Cancer Res Treat. 2012 Sep;44(3):157-65. doi: 10.4143/crt.2012.44.3.157. Epub 2012 Sep 30.

11.

Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

PLoS One. 2012;7(10):e47068. doi: 10.1371/journal.pone.0047068. Epub 2012 Oct 5.

12.

Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis.

van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB.

Gynecol Oncol. 2003 Apr;89(1):140-7. Erratum in: Gynecol Oncol. 2004 Feb;92(2):730.

PMID:
12694668
13.

Cell cycle regulators in bladder cancer: relationship to schistosomiasis.

Eissa S, Ahmed MI, Said H, Zaghlool A, El-Ahmady O.

IUBMB Life. 2004 Sep;56(9):557-64.

14.

Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.

Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ.

Int J Gynecol Pathol. 2011 May;30(3):205-17. doi: 10.1097/PGP.0b013e3182063e71.

PMID:
21464733
15.

Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP.

Oncotarget. 2016 Feb 9;7(6):6593-608. doi: 10.18632/oncotarget.6565.

16.

Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer.

Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N.

Int J Oncol. 1998 May;12(5):1111-6.

PMID:
9538137
17.
18.

Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.

Kim HS, Lee HS, Nam KH, Choi J, Kim WH.

Anticancer Res. 2015 Jun;35(6):3501-10.

PMID:
26026117
19.

Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.

Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M.

Hepatology. 1999 Jul;30(1):90-9.

PMID:
10385644
20.

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors.

Kim HS, Lee HS, Nam KH, Choi J, Kim WH.

Cancer Res Treat. 2014 Oct;46(4):383-92. doi: 10.4143/crt.2013.102. Epub 2014 Jul 17.

Supplemental Content

Support Center